Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403559 · ClinicalTrials.gov registry record · Phase 2
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
A Phase 2 study, sponsored by Dermatology Specialists Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
NCT00403559: Completed Phase 2 study, sponsored by Dermatology Specialists Research.
NCT00403559 is a Phase 2 study that has completed, run by Dermatology Specialists Research. The registered enrollment target is 113 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00403559, a Phase 2 study, has completed, sponsored by Dermatology Specialists Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
Study Summary
This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis
Primary Outcome
F-IGA is defined as Facial Investigator's Global Assessment, which incorporates assessments of the severity of facial seborrheic dermatitis. Scoring is 0 to 3, 0 describing a better outcome with progressively worsening up to 3 representing a worse outcome (whole number only). 0 = Clear; 1 = Mild; 2 = Moderate and 3 = Severe. Scoring is based upon morphologic description of signs of erythema (0 =none, 1= faint, 2 =dull, 3 =deep/dark red) and scaling (0 = none, 1 = minute, powdery scale, 2 = thin
Interventions
- DRUG Elidel
- DRUG Ketoconazole Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2007-05-07 |
| Est. Completion | 2009-02-27 |
| Phase | Phase 2 |
What the finished NCT00403559 record still lists
NCT00403559 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 2 interventions - of which Elidel is the first listed.
NCT00403559 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00403559 about?
NCT00403559 is a clinical study titled "A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis". This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis
What is the current status of trial NCT00403559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2007-05-07. Estimated completion is 2009-02-27.
What interventions are being tested in trial NCT00403559?
The interventions under investigation include: Elidel (DRUG), Ketoconazole Cream (DRUG).
Who is sponsoring clinical trial NCT00403559?
This trial is sponsored by Dermatology Specialists Research, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00403559's enrollment target sits among peer trials
113 631st of 2000 higher than 1,370 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI